Innovassynth Technologies (India) Ltd

BSE: 533315

₹ 157.2-2.00%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 1,460 crWebsite: www.innovassynthinvestments.inUpdated: 24 Oct 2026

About

Innovassynth Technologies (India) Ltd runs Life Sciences, Specialty Chemicals and CRDMO businesses and serves contract development and manufacturing (CDMO) customers. About 90% of its revenue came from global markets, mainly the USA and EU, as of Q4 FY26. It reported FY26 revenue of Rs 102.35 cr.^[1][2]

Order book

Open order book was ~Rs 176 cr in Q4 FY26, up about Rs 60 cr in the quarter.^[1]
Order book split in Q4 FY26: Life Sciences ~Rs 126 cr, CRDMO ~Rs 28 cr, Specialty Chemicals ~Rs 22 cr.^[1]

Customers and markets

About 90% of revenue came from global markets in Q4 FY26, mainly the USA and EU, and existing customers continued to place repeat orders.^[1]
Two large CDMO customers completed audits with no major observations, as of Q4 FY26. Two more audits are scheduled.^[1]
As of Q4 FY26, customer molecules are moving toward commercial production.^[1]

Expansion

As of Q4 FY26, a Life Sciences capacity expansion is underway and is expected to double capacity, in line with CDMO demand.^[1]

Recent developments

In Q3 FY26, shipments were delayed by logistics disruption from the Middle East conflict, and a key customer made a one-time inventory adjustment.^[1]
Quarterly revenue was Rs 50.83 cr in Q4 FY26, compared with Rs 21.97 cr in Q3 FY26, as shipments resumed.^[1]
The company expects operational efficiency initiatives to largely offset the extra costs from the Middle East conflict (stated in Q4 FY26).^[1]

Market Cap

₹1,460 Cr

High / Low

₹180 / 45

Stock P/E

-109.9

Price / Book

0.0

Book Value

₹10

EPS

₹-3.1

No. of Shares

9.29 Cr

ROCE

-25.0%

ROE

-41.8%

Sales

₹102 Cr

Net Profit

₹-29 Cr

Promoter holding

75.0%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials